Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 - AML
    • KOMET-007 - AML
    • KOMET-008 - AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN - HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 - Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
      • Calendar Events
      • Corporate Presentations
      • Scientific Publications
    • Corporate Governance
      • Committees and Governance Documents
      • Board of Directors
      • Leadership Team
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Contact
    Top Links
    • News & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Ziftomenib
      • Tipifarnib
      • KO-2806
      • Posters and Presentations
      • Scientific Manuscripts
      • Access To Investigational Drugs Outside a Clinical Study
    • Clinical Trials
      • Overview of Clinical Trials
      • Ziftomenib Clinical Trials
      • KOMET-001 - AML
      • KOMET-007 - AML
      • KOMET-008 - AML
      • Tipifarnib Clinical Trials
      • KURRENT-HN - HNSCC
      • KO-2806 Clinical Trials
      • FIT-001 - Solid Tumors
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Investors
      • Overview
      • Press Releases
      • Events & Presentations
        • Calendar Events
        • Corporate Presentations
        • Scientific Publications
      • Corporate Governance
        • Committees and Governance Documents
        • Board of Directors
        • Leadership Team
      • Financial Information
      • Analyst Coverage
      • FAQs
      • Contact
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Contact
    • MenuMenu

    SEC Filing Details

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts

    Document Details

    Form
    8-K
    Filing Date
    11-03-2022
    Document Date
    11-03-2022
    Form Description
    Report of unscheduled material events or corporate event
    Filing Group
    Current Reports
    Company
    Kura Oncology, Inc.
    Issuer
    Kura Oncology, Inc.

    Filing Formats

    iXBRL
    View HTML
    Download PDF
    Download DOC
    Download XLS

    XBRL

    XBRL Viewer
    EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
    EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE
    EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
    XML - XBRL INSTANCE DOCUMENT

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    Footer Links - Clinical Trials
    • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 - AML
    • KOMET-008 - AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 - Solid Tumors
    Footer Links - Investors
    • News & Media
    • Press Releases
    • News & Perspecitives
    • Expert Perspectives
    • Media Resources
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc.
    12730 High Bluff Drive, Suite 400
    San Diego, CA 92130
    (858) 500-8800

    Kura Oncology, Inc.
    2 Seaport Lane, Suite 8A
    Boston, MA 02210
    (617) 588-3755

    Kura Oncology, Inc.
    5510 Morehouse Drive, Suite 110
    San Diego, California 92121

    © 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy

    Scroll to top